{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-060195","form_type":"8-K","ticker":"APGE","cik":"0001974640","company_name":"Apogee Therapeutics, Inc.","filed_at":"2024-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.353477+00:00","generated_at":"2026-06-02T02:51:35.598178+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Apogee reports Q1 net loss $32.1M, cash $816M, advances pipeline with Phase 2 start for APG777 and $483M raise","bullets":["Net loss $32.1M vs $12.5M YoY; R&D expenses $28.7M (up from $8.5M) as pipeline progresses.","Cash, equivalents and marketable securities $816.2M; runway into early 2028.","Completed upsized public offering raising $483M gross proceeds at $62.00/share.","Initiated Phase 2 trial of APG777 (IL-13) in atopic dermatitis; proof-of-concept data expected 2H 2025.","Dosed first participant in Phase 1 trial of APG808 (IL-4Rα); interim data expected 2H 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-060195","json":"https://secwatch.observer/filing/0001104659-24-060195.json","markdown":"https://secwatch.observer/filing/0001104659-24-060195.md","text":"https://secwatch.observer/filing/0001104659-24-060195.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1974640/000110465924060195/0001104659-24-060195-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1974640/000110465924060195/tm2414075d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T02:51:35.598178+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d6590d7a00c985dfedf51185264a3dbf6376b020","claim":"Apogee Therapeutics, Inc. reported financial results for first quarter 2024.","evidence_excerpt":"On May 13, 2024, Apogee Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465924060195/0001104659-24-060195-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter 2024"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}